174 related articles for article (PubMed ID: 30701374)
1. First-year weight loss with androgen-deprivation therapy increases risks of prostate cancer progression and prostate cancer-specific mortality: results from SEARCH.
Griffin K; Csizmadi I; Howard LE; Pomann GM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Beebe-Dimmer J; Freedland SJ
Cancer Causes Control; 2019 Mar; 30(3):259-269. PubMed ID: 30701374
[TBL] [Abstract][Full Text] [Related]
2. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2012 Aug; 110(4):492-8. PubMed ID: 22094083
[TBL] [Abstract][Full Text] [Related]
3. Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer.
Miller ET; Chamie K; Kwan L; Lewis MS; Knudsen BS; Garraway IP
Cancer Med; 2017 Jan; 6(1):163-172. PubMed ID: 27997745
[TBL] [Abstract][Full Text] [Related]
4. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
5. Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy.
Kelkar S; Oyekunle T; Eisenberg A; Howard L; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Klaassen Z; Terris MK; Freedland SJ; Csizmadi I
JNCI Cancer Spectr; 2021 Jun; 5(3):. PubMed ID: 34169227
[TBL] [Abstract][Full Text] [Related]
6. Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?
Vidal AC; Howard LE; De Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Lechpammer S; Flanders SC; Freedland SJ
Cancer; 2019 Feb; 125(3):434-441. PubMed ID: 30427535
[TBL] [Abstract][Full Text] [Related]
7. Short-course androgen deprivation therapy and the risk of death from high-risk prostate cancer in men undergoing external beam radiation therapy and brachytherapy.
Raldow AC; Zhang D; Chen MH; Braccioforte MH; Moran BJ; D'Amico AV
Brachytherapy; 2015; 14(6):781-7. PubMed ID: 26361718
[TBL] [Abstract][Full Text] [Related]
8. Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality.
Mahal BA; Chen MH; Renshaw AA; Loffredo MJ; Kantoff PW; D'Amico AV
J Natl Compr Canc Netw; 2018 Jun; 16(6):727-734. PubMed ID: 29891524
[No Abstract] [Full Text] [Related]
9. Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Vidal AC; Howard LE; Sun SX; Cooperberg MR; Kane CJ; Aronson WJ; Terris MK; Amling CL; Freedland SJ
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):72-78. PubMed ID: 27698439
[TBL] [Abstract][Full Text] [Related]
10. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy and the risk of death from prostate cancer among men with favorable or unfavorable intermediate-risk disease.
Keane FK; Chen MH; Zhang D; Moran BJ; Braccioforte MH; D'Amico AV
Cancer; 2015 Aug; 121(16):2713-9. PubMed ID: 25925789
[TBL] [Abstract][Full Text] [Related]
12. Association between Radical Prostatectomy and Survival in Men with Clinically Node-positive Prostate Cancer.
Sarkar RR; Bryant AK; Parsons JK; Ryan ST; Karim Kader A; Kane CJ; McKay RR; Sandhu A; Murphy JD; Rose BS
Eur Urol Oncol; 2019 Sep; 2(5):584-588. PubMed ID: 31411995
[TBL] [Abstract][Full Text] [Related]
13. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
[TBL] [Abstract][Full Text] [Related]
14. Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort.
Mithal P; Howard LE; Aronson WJ; Terris MK; Cooperberg MR; Kane CJ; Amling C; Freedland SJ
BJU Int; 2016 Feb; 117(2):244-8. PubMed ID: 26010160
[TBL] [Abstract][Full Text] [Related]
15. Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study.
Barlow SK; Oyekunle T; Janes JL; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Klaassen ZW; Terris MK; Freedland SJ; Csizmadi I
Prostate; 2022 Feb; 82(3):366-372. PubMed ID: 34905632
[TBL] [Abstract][Full Text] [Related]
16. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Vidal AC; Howard LE; de Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Freedland SJ
BJU Int; 2018 Jul; 122(1):76-82. PubMed ID: 29521009
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer.
Nair SM; Peters M; Kurver P; Lavi A; Verhoeff JJC; van der Voort van Zyp JRN; van Son MJ; Chin JL
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):186-192. PubMed ID: 32814843
[TBL] [Abstract][Full Text] [Related]
18. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
[TBL] [Abstract][Full Text] [Related]
19. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality.
Bitterman DS; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
Cancer; 2021 Aug; 127(15):2623-2630. PubMed ID: 33823065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
